The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gastric Cancer Therapy Market Research Report 2025
Synopsis
Gastric Cancer Therapy is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as Gastric Cancer Therapy or stomach cancer. Diet and stomach disorders are both risk factors for Gastric Cancer Therapy. Stomach pain, poor appetite, weight loss, indigestions, nausea, vomiting with or without blood are some of the symptoms of Gastric Cancer Therapy.
Global Gastric Cancer Therapy market is projected to reach US$ 1169.8 million in 2029, increasing from US$ 841 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gastric Cancer Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gastric Cancer Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis AG
Glaxo SmithKline Plc
Roche Holding Limited
AptarGroup Incorporated
Squibb Company
Boston Scientific Corporation
Pfizer.
Agilent Technologies, Inc.
Illumina, Inc.
Thermo Fisher Scientific, Inc.
General Electric Company
BD
Abbott
Merck
F. Hoffmann-La Roche Ltd.
Segment by Type
Prescription Drugs
Non-Prescription Drugs
Segment by Application
Online Sales
Offline Sales
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Gastric Cancer Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Gastric Cancer Therapy is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as Gastric Cancer Therapy or stomach cancer. Diet and stomach disorders are both risk factors for Gastric Cancer Therapy. Stomach pain, poor appetite, weight loss, indigestions, nausea, vomiting with or without blood are some of the symptoms of Gastric Cancer Therapy.
Global Gastric Cancer Therapy market is projected to reach US$ 1169.8 million in 2029, increasing from US$ 841 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gastric Cancer Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gastric Cancer Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis AG
Glaxo SmithKline Plc
Roche Holding Limited
AptarGroup Incorporated
Squibb Company
Boston Scientific Corporation
Pfizer.
Agilent Technologies, Inc.
Illumina, Inc.
Thermo Fisher Scientific, Inc.
General Electric Company
BD
Abbott
Merck
F. Hoffmann-La Roche Ltd.
Segment by Type
Prescription Drugs
Non-Prescription Drugs
Segment by Application
Online Sales
Offline Sales
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Gastric Cancer Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Gastric Cancer Therapy Market Overview
1.1 Product Overview and Scope of Gastric Cancer Therapy
1.2 Gastric Cancer Therapy Segment by Type
1.2.1 Global Gastric Cancer Therapy Market Value Comparison by Type (2023-2029)
1.2.2 Prescription Drugs
1.2.3 Non-Prescription Drugs
1.3 Gastric Cancer Therapy Segment by Application
1.3.1 Global Gastric Cancer Therapy Market Value by Application: (2023-2029)
1.3.2 Online Sales
1.3.3 Offline Sales
1.4 Global Gastric Cancer Therapy Market Size Estimates and Forecasts
1.4.1 Global Gastric Cancer Therapy Revenue 2018-2029
1.4.2 Global Gastric Cancer Therapy Sales 2018-2029
1.4.3 Global Gastric Cancer Therapy Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Gastric Cancer Therapy Market Competition by Manufacturers
2.1 Global Gastric Cancer Therapy Sales Market Share by Manufacturers (2018-2023)
2.2 Global Gastric Cancer Therapy Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Gastric Cancer Therapy Average Price by Manufacturers (2018-2023)
2.4 Global Gastric Cancer Therapy Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Gastric Cancer Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gastric Cancer Therapy, Product Type & Application
2.7 Gastric Cancer Therapy Market Competitive Situation and Trends
2.7.1 Gastric Cancer Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gastric Cancer Therapy Players Market Share by Revenue
2.7.3 Global Gastric Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gastric Cancer Therapy Retrospective Market Scenario by Region
3.1 Global Gastric Cancer Therapy Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Gastric Cancer Therapy Global Gastric Cancer Therapy Sales by Region: 2018-2029
3.2.1 Global Gastric Cancer Therapy Sales by Region: 2018-2023
3.2.2 Global Gastric Cancer Therapy Sales by Region: 2024-2029
3.3 Global Gastric Cancer Therapy Global Gastric Cancer Therapy Revenue by Region: 2018-2029
3.3.1 Global Gastric Cancer Therapy Revenue by Region: 2018-2023
3.3.2 Global Gastric Cancer Therapy Revenue by Region: 2024-2029
3.4 North America Gastric Cancer Therapy Market Facts & Figures by Country
3.4.1 North America Gastric Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Gastric Cancer Therapy Sales by Country (2018-2029)
3.4.3 North America Gastric Cancer Therapy Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gastric Cancer Therapy Market Facts & Figures by Country
3.5.1 Europe Gastric Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Gastric Cancer Therapy Sales by Country (2018-2029)
3.5.3 Europe Gastric Cancer Therapy Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastric Cancer Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific Gastric Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Gastric Cancer Therapy Sales by Country (2018-2029)
3.6.3 Asia Pacific Gastric Cancer Therapy Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Gastric Cancer Therapy Market Facts & Figures by Country
3.7.1 Latin America Gastric Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Gastric Cancer Therapy Sales by Country (2018-2029)
3.7.3 Latin America Gastric Cancer Therapy Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gastric Cancer Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastric Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Gastric Cancer Therapy Sales by Country (2018-2029)
3.8.3 Middle East and Africa Gastric Cancer Therapy Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gastric Cancer Therapy Sales by Type (2018-2029)
4.1.1 Global Gastric Cancer Therapy Sales by Type (2018-2023)
4.1.2 Global Gastric Cancer Therapy Sales by Type (2024-2029)
4.1.3 Global Gastric Cancer Therapy Sales Market Share by Type (2018-2029)
4.2 Global Gastric Cancer Therapy Revenue by Type (2018-2029)
4.2.1 Global Gastric Cancer Therapy Revenue by Type (2018-2023)
4.2.2 Global Gastric Cancer Therapy Revenue by Type (2024-2029)
4.2.3 Global Gastric Cancer Therapy Revenue Market Share by Type (2018-2029)
4.3 Global Gastric Cancer Therapy Price by Type (2018-2029)
5 Segment by Application
5.1 Global Gastric Cancer Therapy Sales by Application (2018-2029)
5.1.1 Global Gastric Cancer Therapy Sales by Application (2018-2023)
5.1.2 Global Gastric Cancer Therapy Sales by Application (2024-2029)
5.1.3 Global Gastric Cancer Therapy Sales Market Share by Application (2018-2029)
5.2 Global Gastric Cancer Therapy Revenue by Application (2018-2029)
5.2.1 Global Gastric Cancer Therapy Revenue by Application (2018-2023)
5.2.2 Global Gastric Cancer Therapy Revenue by Application (2024-2029)
5.2.3 Global Gastric Cancer Therapy Revenue Market Share by Application (2018-2029)
5.3 Global Gastric Cancer Therapy Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Corporation Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novartis AG Gastric Cancer Therapy Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 Glaxo SmithKline Plc
6.2.1 Glaxo SmithKline Plc Corporation Information
6.2.2 Glaxo SmithKline Plc Description and Business Overview
6.2.3 Glaxo SmithKline Plc Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Glaxo SmithKline Plc Gastric Cancer Therapy Product Portfolio
6.2.5 Glaxo SmithKline Plc Recent Developments/Updates
6.3 Roche Holding Limited
6.3.1 Roche Holding Limited Corporation Information
6.3.2 Roche Holding Limited Description and Business Overview
6.3.3 Roche Holding Limited Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Roche Holding Limited Gastric Cancer Therapy Product Portfolio
6.3.5 Roche Holding Limited Recent Developments/Updates
6.4 AptarGroup Incorporated
6.4.1 AptarGroup Incorporated Corporation Information
6.4.2 AptarGroup Incorporated Description and Business Overview
6.4.3 AptarGroup Incorporated Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 AptarGroup Incorporated Gastric Cancer Therapy Product Portfolio
6.4.5 AptarGroup Incorporated Recent Developments/Updates
6.5 Squibb Company
6.5.1 Squibb Company Corporation Information
6.5.2 Squibb Company Description and Business Overview
6.5.3 Squibb Company Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Squibb Company Gastric Cancer Therapy Product Portfolio
6.5.5 Squibb Company Recent Developments/Updates
6.6 Boston Scientific Corporation
6.6.1 Boston Scientific Corporation Corporation Information
6.6.2 Boston Scientific Corporation Description and Business Overview
6.6.3 Boston Scientific Corporation Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boston Scientific Corporation Gastric Cancer Therapy Product Portfolio
6.6.5 Boston Scientific Corporation Recent Developments/Updates
6.7 Pfizer.
6.6.1 Pfizer. Corporation Information
6.6.2 Pfizer. Description and Business Overview
6.6.3 Pfizer. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer. Gastric Cancer Therapy Product Portfolio
6.7.5 Pfizer. Recent Developments/Updates
6.8 Agilent Technologies, Inc.
6.8.1 Agilent Technologies, Inc. Corporation Information
6.8.2 Agilent Technologies, Inc. Description and Business Overview
6.8.3 Agilent Technologies, Inc. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Agilent Technologies, Inc. Gastric Cancer Therapy Product Portfolio
6.8.5 Agilent Technologies, Inc. Recent Developments/Updates
6.9 Illumina, Inc.
6.9.1 Illumina, Inc. Corporation Information
6.9.2 Illumina, Inc. Description and Business Overview
6.9.3 Illumina, Inc. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Illumina, Inc. Gastric Cancer Therapy Product Portfolio
6.9.5 Illumina, Inc. Recent Developments/Updates
6.10 Thermo Fisher Scientific, Inc.
6.10.1 Thermo Fisher Scientific, Inc. Corporation Information
6.10.2 Thermo Fisher Scientific, Inc. Description and Business Overview
6.10.3 Thermo Fisher Scientific, Inc. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Thermo Fisher Scientific, Inc. Gastric Cancer Therapy Product Portfolio
6.10.5 Thermo Fisher Scientific, Inc. Recent Developments/Updates
6.11 General Electric Company
6.11.1 General Electric Company Corporation Information
6.11.2 General Electric Company Gastric Cancer Therapy Description and Business Overview
6.11.3 General Electric Company Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.11.4 General Electric Company Gastric Cancer Therapy Product Portfolio
6.11.5 General Electric Company Recent Developments/Updates
6.12 BD
6.12.1 BD Corporation Information
6.12.2 BD Gastric Cancer Therapy Description and Business Overview
6.12.3 BD Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.12.4 BD Gastric Cancer Therapy Product Portfolio
6.12.5 BD Recent Developments/Updates
6.13 Abbott
6.13.1 Abbott Corporation Information
6.13.2 Abbott Gastric Cancer Therapy Description and Business Overview
6.13.3 Abbott Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Abbott Gastric Cancer Therapy Product Portfolio
6.13.5 Abbott Recent Developments/Updates
6.14 Merck
6.14.1 Merck Corporation Information
6.14.2 Merck Gastric Cancer Therapy Description and Business Overview
6.14.3 Merck Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Merck Gastric Cancer Therapy Product Portfolio
6.14.5 Merck Recent Developments/Updates
6.15 F. Hoffmann-La Roche Ltd.
6.15.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.15.2 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Description and Business Overview
6.15.3 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.15.4 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Product Portfolio
6.15.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastric Cancer Therapy Industry Chain Analysis
7.2 Gastric Cancer Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastric Cancer Therapy Production Mode & Process
7.4 Gastric Cancer Therapy Sales and Marketing
7.4.1 Gastric Cancer Therapy Sales Channels
7.4.2 Gastric Cancer Therapy Distributors
7.5 Gastric Cancer Therapy Customers
8 Gastric Cancer Therapy Market Dynamics
8.1 Gastric Cancer Therapy Industry Trends
8.2 Gastric Cancer Therapy Market Drivers
8.3 Gastric Cancer Therapy Market Challenges
8.4 Gastric Cancer Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
